Acquisitions - Additional Information (Details) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
	Sep. 30, 2020	Feb. 28, 2019	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Business Acquisition [Line Items]
Estimated fair value of contingent consideration, short term liabilities			$ 43,459,000		$ 43,459,000
Estimated fair value of contingent consideration, long-term liabilities			88,522,000		88,522,000		$ 121,901,000
Change in the estimated fair value of contingent consideration					10,080,000	$ 16,672,000
Oscine Corp
Business Acquisition [Line Items]
Business acquisition, consideration transferred	$ 8,500,000
Oscine Corp | Stock Purchase Agreement
Business Acquisition [Line Items]
Business acquisition, percentage of voting interests acquired	100.00%			100.00%		100.00%
Business acquisition, consideration transferred	$ 8,500,000			$ 8,500,000
Business acquisition, consideration transferred, cash	7,600,000
Business acquisition, consideration holdback amount	900,000
Oscine Corp | Stock Purchase Agreement | Maximum
Business Acquisition [Line Items]
Future milestone payments upon achievement of certain development and commercial milestones	$ 225,800,000			225,800,000		$ 225,800,000
Cobalt Biomedicine, Inc | Acquisition Agreement
Business Acquisition [Line Items]
Business acquisition, percentage of voting interests acquired		100.00%
Maximum success payment upon achievement of certain pre-specified development milestones		$ 500,000,000.0
Maximum period for success payment to achieve		20 years
Cobalt Biomedicine, Inc | Acquisition Agreement | Research and Development
Business Acquisition [Line Items]
Estimated fair value of success payment liability			111,600,000		111,600,000		64,700,000
Estimated fair value of contingent consideration			132,000,000.0		132,000,000.0		$ 121,900,000
Estimated fair value of contingent consideration, short term liabilities			43,500,000		43,500,000
Estimated fair value of contingent consideration, long-term liabilities			88,500,000		88,500,000
(Gain) expense in connection with change in estimated fair value of success payment			21,800,000	1,300,000	46,900,000	35,200,000
Change in the estimated fair value of contingent consideration			$ 8,500,000	$ 2,300,000	$ 10,100,000	$ 16,700,000
Cobalt Biomedicine, Inc | Acquisition Agreement | Market Capitalization Equal to or Exceeds $8.1 billion
Business Acquisition [Line Items]
Cobalt success payment		$ 500,000,000.0
Cobalt Biomedicine, Inc | Acquisition Agreement | Minimum [Member]
Business Acquisition [Line Items]
Threshold market capitalization		$ 8,100,000,000